HC Wainwright & Co. Reiterates Buy on Gracell Biotechnologies, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on Gracell Biotechnologies (NASDAQ:GRCL) and maintains a $12 price target.
May 26, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on Gracell Biotechnologies and maintains a $12 price target.
The reiterated Buy rating and maintained $12 price target by HC Wainwright & Co. analyst Emily Bodnar indicates a positive outlook for Gracell Biotechnologies. This news is likely to have a positive short-term impact on the stock price as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100